COMBATING RECALCITRANT CANCER TYPES THROUGH RATIONAL ENGINEERING OF ANTIBODY-DRUG CONJUGATES

$77,587FY2020Defense Health AgencyDOD

The Geneva Foundation

Investigators

View source on USAspending →